Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04923100
Status:
RECRUITING
Last Update Posted:
2023-12-05
First Post:
2021-06-07
Brief Title:
Therapeutic Effect of New Biologics in Crohns Disease
Sponsor:
Sixth Affiliated Hospital Sun Yat-sen University
Organization:
Sixth Affiliated Hospital Sun Yat-sen University
Study Overview
Official Title:
Therapeutic Effect of New Biologics in Crohns Disease
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
New types of biologics have brought advantages in therapy strategies for Crohns disease However clinical data evaluating their efficacy and adverse in China is lacking We aimed to evaluate the short-term and long-term therapeutic effect as well as drug adverse of Ustekinumab UST and Vedolizumab VED Besides we aim to figure out the independent factors predicting the effectiveness of new biologics Relations between drug exposure trough concentration and antibody concentration and therapeutic efficacy are study in-depth by this retrospective observational study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None